Inhibition of casein kinase 2 prevents growth of human osteosarcoma

  • Authors:
    • Kengo Takahashi
    • Takao Setoguchi
    • Arisa Tsuru
    • Yoshinobu Saitoh
    • Satoshi Nagano
    • Yasuhiro Ishidou
    • Shingo Maeda
    • Tatsuhiko Furukawa
    • Setsuro Komiya
  • View Affiliations

  • Published online on: December 9, 2016     https://doi.org/10.3892/or.2016.5310
  • Pages: 1141-1147
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High-dose chemotherapy and surgical treatment have improved the prognosis of osteosarcoma. However, more than 20% of patients with osteosarcoma still have a poor prognosis. We investigated the expression and function of casein kinase 2 (CK2) in osteosarcoma growth. We then examined the effects of CX-4945, a CK2 inhibitor, on osteosarcoma growth in vitro and in vivo to apply our findings to the clinical setting. We examined the expression of CK2α and CK2β by western blot analysis, and performed WST-1 assays using CK2α and CK2β siRNA or CX-4945. Flow cytometry and western blot analyses were performed to evaluate apoptotic cell death. Xenograft models were used to examine the effect of CX-4945 in vivo. Western blot analysis revealed upregulation of CK2α and CK2β in human osteosarcoma cell lines compared with human osteoblast cells or mesenchymal stem cells. WST assay showed that knockdown of CK2α or CK2β by siRNA inhibited the proliferation of human osteosarcoma cells. Treatment with 3 µM of CX-4945 inhibited osteosarcoma cell proliferation; however, the same concentration of CX-4945 did not affect the proliferation of human mesenchymal stem cells. Additionally, treatment with CX-4945 inhibited the proliferation of human osteosarcoma cells in a dose-dependent manner. Western blot and flow cytometry analyses showed that treatment with CX-4945 promoted apoptotic death of osteosarcoma cells. The xenograft model showed that treatment with CX-4945 significantly prevented osteosarcoma growth in vivo compared with control vehicle treatment. Our findings indicate that CK2 may be an attractive therapeutic target for treating osteosarcoma.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 37 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T and Komiya S: Inhibition of casein kinase 2 prevents growth of human osteosarcoma. Oncol Rep 37: 1141-1147, 2017
APA
Takahashi, K., Setoguchi, T., Tsuru, A., Saitoh, Y., Nagano, S., Ishidou, Y. ... Komiya, S. (2017). Inhibition of casein kinase 2 prevents growth of human osteosarcoma. Oncology Reports, 37, 1141-1147. https://doi.org/10.3892/or.2016.5310
MLA
Takahashi, K., Setoguchi, T., Tsuru, A., Saitoh, Y., Nagano, S., Ishidou, Y., Maeda, S., Furukawa, T., Komiya, S."Inhibition of casein kinase 2 prevents growth of human osteosarcoma". Oncology Reports 37.2 (2017): 1141-1147.
Chicago
Takahashi, K., Setoguchi, T., Tsuru, A., Saitoh, Y., Nagano, S., Ishidou, Y., Maeda, S., Furukawa, T., Komiya, S."Inhibition of casein kinase 2 prevents growth of human osteosarcoma". Oncology Reports 37, no. 2 (2017): 1141-1147. https://doi.org/10.3892/or.2016.5310